| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 4,210 | 2,781 | 12,768 | 23,194 |
| Research and development | 44,069 | 41,979 | 36,678 | 30,653 |
| General and administrative | 10,175 | 10,517 | 9,065 | 8,095 |
| Total operating expenses | 54,244 | 52,496 | 45,743 | 38,748 |
| (loss) income from operations | -50,034 | -49,715 | -32,975 | -15,554 |
| Interest income | 5,591 | 3,689 | 2,746 | 3,068 |
| Foreign currency exchange (gain) loss | -8 | -50 | -29 | 1,390 |
| Gain on disposal of property and equipment | 0 | 0 | 0 | 0 |
| Total other income | 5,583 | 3,639 | 2,717 | 4,458 |
| Net (loss) income before income taxes | -44,451 | -46,076 | -30,258 | -11,096 |
| Income tax benefit (provision) | 52 | 59 | -3,177 | 1,199 |
| Net (loss) income | -44,503 | -46,135 | -27,081 | -12,295 |
| Unrealized loss on available-for-sale securities | NaN | NaN | NaN | 97 |
| Provision for pension benefit obligation | -55 | -690* | 53 | 53 |
| Unrealized gain (loss) on available-for-sale securities | NaN | NaN | 73 | NaN |
| Unrealized loss on available-for-sale securities | 974 | -110* | NaN | NaN |
| Comprehensive (loss) income | -45,422 | -46,715 | -26,955 | -12,339 |
| Basic Average Shares | 99,883,878 | 85,551,500 | 82,397,753 | 82,186,768 |
| Diluted Average Shares | 99,883,878 | 84,743,796 | 82,397,753 | 82,186,768 |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)